Matthew A. Gonda

PreMD, Inc. engages in manufacturing and distribution of pharmaceutical products. The company was founded by H. B. Brent Norton on November 9, 1992 and is headquartered in Toronto, Canada.

Part of Innoviva, Inc., Genovo, Inc. is a maker of gene and cell therapy products. The company is based in Sharon Hill, PA. Genovo was acquired by AmpliPhi Biosciences Corp. on September 20, 2000 for $84.53 million.

TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.

Altimmune, Inc. develops vaccines and other biological products. The firm offers products for use in companion and commercial livestock, including cats, dogs, horses, swine, poultry and aquaculture. The company was founded by G. Michael Alder and De-chu Tang in 1997 and is headquartered in Gaithersburg, MD.

DiscoveryBioMed, Inc. provides human cell-based drug discovery services. It provides pilot screening and high-throughput screening services for therapeutic-related bioassays, custom immortalized cell lines and therapeutics discovery for certain failure-to-secrete diseases in humans. The company was founded by Erik M. Schwiebert in October 2007 and is headquartered in Birmingham, AL.

Amytrx Therapeutics, Inc. developed biological medicines. The company was headquartered in Nashville, TN.